Cancer Vaccines: A Ray of Hope

Editorial

Austin J Cancer Clin Res 2014;1(1): 1005.

Cancer Vaccines: A Ray of Hope

Lipika Chablani

Department of Pharmaceutical Sciences, Wegmans School of Pharmacy, USA

*Corresponding author: Lipika Chablani , Department of Pharmaceutical Sciences, Wegmans School of Pharmacy, St. John Fisher College, Rochester, NY 14618

Received: December 17, 2013; Accepted: January 10, 2014; Published: January 12, 2014

As we put forth the inaugural issue of Austin Journal of Cancer and Clinical Research, I would like to take this opportunity to welcome the readers and encourage fellow peers in academia, industry, government and related healthcare professionals to contribute their research work and expert reviews to the journal.

Recent cancer statistics review by Surveillance, Epidemiology, and End Results (SEER) Program by National Cancer Institute (NCI) shows that cancer is the second most leading cause of death after heart diseases. Cancer incidence has grown from 19.2% to 23.3% from 1975 to 2010 (Figure 1)[1]. Lung cancer remains to be the most fatal form of cancer followed by colorectal, breast and prostate cancer in the country (Table 1)[1]. Regardless of several treatment options, cancer remains to be a unique challenge for both patients and the healthcare providers. Several treatment options are available to address this disease now. Chemotherapy, surgery, radiation therapy are still the mainline of treatment plan for cancer patients. Along with these therapies, immunotherapy is being explored as a combination therapy. Immunotherapy allows utilization of patient’s own immune system to combat the disease and⁄or assist in avoiding a relapse.

Citation: Chablani L. Cancer Vaccines: A Ray of Hope. Austin J Cancer Clin Res 2014;1(1): 1005. ISSN 2381-909X